Brainomix

Brainomix specializes in developing AI-powered software solutions to enable precision medicine, improving treatment decisions for stroke and lung fibrosis patients. Originating as a spinout from the University of Oxford, the company has grown into a commercial-stage organization with offices in the UK, Ireland, and the USA, and a presence in over 20 countries. Backed by leading healthtech investors, Brainomix has created award-winning imaging biomarkers and software solutions that are now clinically adopted in hundreds of hospitals globally.

Its flagship product, the Brainomix 360 stroke platform, offers the most comprehensive stroke imaging solution available. By enhancing diagnostic accuracy and treatment planning, the platform has driven increased treatment rates and improved functional independence for stroke patients. Brainomix continues to innovate, leveraging AI to advance precision medicine and improve outcomes for patients with complex medical conditions.